GlassScriptPhysician profile
Ryan O Mcdonald
NPI 1154595270
$10,188.93
in general payments reported to CMS, 2019-2025
56 companies · $3,306 in 2025
The $3,306 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $406 · 2021: $608 · 2022: $1,473 · 2023: $2,095 · 2024: $2,176 · 2025: $3,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,577.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,325.18 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,242.51 | 2020-2025 | |
| Eisai INC. | $673.64 | 2020-2025 | |
| Harmony Biosciences LLC | $522.49 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $435.36 | 2023-2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $366.16 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $347.96 | 2023-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $341.25 | 2020-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $338.34 | 2023-2025 | |
| Emd Serono, INC. | $315.79 | 2020-2025 | Mavenclad |
| Lilly USA, LLC | $306.63 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $250.09 | 2020-2024 | Vumerity, Tysabri, Avonex |
| Biohaven Pharmaceutical Holding Company LTD. | $244.77 | 2022 | |
| Argenx US, INC. | $205.35 | 2022-2025 | Vyvgart Hytrulo |
| Grifols USA, LLC | $202.26 | 2022-2025 | Gamunex-C |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $193.59 | 2023-2025 | Symbravo, Sunosi |
| Genentech USA, INC. | $193.52 | 2021-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Takeda Pharmaceuticals U.S.A., INC. | $193.14 | 2023-2025 | Hyqvia, Gammagard |
| Tg Therapeutics, INC. | $190.47 | 2025 | |
| Sk Life Science, INC. | $179.85 | 2020-2023 | |
| Ucb, INC. | $161.19 | 2021-2025 | Rystiggo |
| Lundbeck LLC | $131.97 | 2020-2025 | Vyepti |
| Merz Pharmaceuticals, LLC | $124.23 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Acadia Pharmaceuticals INC | $123.27 | 2021-2025 | Nuplazid |
| Jazz Pharmaceuticals INC. | $121.19 | 2023-2025 | |
| Genzyme Corporation | $107.79 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $106.63 | 2022-2024 | Qelbree |
| Amgen INC. | $97.81 | 2022-2025 | Uplizna, Repatha |
| Otsuka America Pharmaceutical, INC. | $90.37 | 2024-2025 | Rexulti |
| Aucta Pharmaceuticals, INC. | $83.33 | 2024-2025 | Motpoly Xr |
| Allergan, INC. | $81.61 | 2020-2021 | |
| Ge Healthcare | $78.65 | 2023 | |
| Azurity Pharmaceuticals, INC. | $71.07 | 2024-2025 | Horizant |
| Acorda Therapeutics, INC | $68.85 | 2022-2023 | Inbrija, Ampyra |
| Avion Pharmaceuticals | $64.45 | 2022-2023 | Dhivy |
| Astrazeneca Pharmaceuticals LP | $57.83 | 2022-2023 | Andexxa |
| Biohaven Pharmaceuticals, INC. | $55.41 | 2020-2021 | |
| Corium, LLC | $52.31 | 2023 | Adlarity |
| Livanova USA, INC. | $40.75 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mdd US Operations, LLC | $38.11 | 2023-2024 | Gocovri, Apokyn |
| Amneal Pharmaceuticals LLC | $35.57 | 2025 | Brekiya, Crexont |
| E.R. Squibb & Sons, L.L.C. | $33.06 | 2020 | |
| Grt US Holding, INC. | $30.09 | 2022 | |
| Celgene Corporation | $26.73 | 2025 | Zeposia |
| Amylyx Pharmaceuticals, INC. | $23.58 | 2023 | Relyvrio |
| Janssen Pharmaceuticals, INC | $22.94 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $22.62 | 2024 | |
| Avanir Pharmaceuticals, INC. | $22.62 | 2022 | |
| Impel Pharmaceuticals LLC | $22.36 | 2025 | Trudhesa |
| Merz North America, INC. | $21.92 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.65 | 2025 | Rexulti |
| Medtronic, INC. | $20.12 | 2022 | |
| Vanda Pharmaceuticals INC. | $19.13 | 2024 | Ponvory |
| Zoll Respicardia, INC. | $17.27 | 2024 | Remede System |
| Strongbridge US INC. | $14.67 | 2019 | |
| Life Molecular Imaging LTD | $10.43 | 2023 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.